<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04254354</url>
  </required_header>
  <id_info>
    <org_study_id>BICTX01</org_study_id>
    <nct_id>NCT04254354</nct_id>
  </id_info>
  <brief_title>Transgender Men, Non-binary Persons and Testosterone Treatment BODY IDENTITY CLINIC</brief_title>
  <official_title>Masculinizing Testosterone Treatment and Effects on Preclinical Cardiovascular Disease, Muscle Strength and Power, Aggression, Physical Fitness and Respiratory Function in Transgender Men,Body Identity Clinic (BIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marianne Andersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate transgender men and non-binary persons before and&#xD;
      during testosterone treatment. The study will focus on:&#xD;
&#xD;
        -  Cardiovascular status&#xD;
&#xD;
        -  Muscle strenght and power&#xD;
&#xD;
        -  Aggression and quality of life&#xD;
&#xD;
        -  Cardiac and respiratory function&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: The number of individuals with gender dysphoria seeking gender-affirming&#xD;
      treatment is increasing. The short- and long-term effects of masculinizing treatment with&#xD;
      testosterone are debated as serum testosterone increase up to 20-fold compared to cisgender&#xD;
      women. We hypothesize that, testosterone treatment is associated with non-calcified coronary&#xD;
      plaque (NCP) development in transgender men.&#xD;
&#xD;
      Methods and analyses: Prospective, single-center, observational cohort study at the Body&#xD;
      Identity Clinic (BIC), Odense University Hospital, Denmark, where all investigations are&#xD;
      performed at inclusion and after 1, 3, 5 and 10 years of testosterone therapy.&#xD;
&#xD;
      Ethics and dissemination: The Regional Committees on Health Research Ethics for Southern&#xD;
      Denmark (S-20190108) and the Danish Data Protection Agency approved the study (19/27572).&#xD;
      Signed informed consent will be obtained from all participants. All findings will be&#xD;
      published in peer-reviewed journals or at scientific conferences.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2044</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2044</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of testosterone on devellopment of plaques in the heart</measure>
    <time_frame>10 years</time_frame>
    <description>Estimated directly by CCTA, at start, 1 year and 10 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calcium score</measure>
    <time_frame>10 years</time_frame>
    <description>CCTA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle strength and power</measure>
    <time_frame>10 years</time_frame>
    <description>Estimated by low row and accelometer at start, 1, 3, 5, 10 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of transgender treatment on quality of life</measure>
    <time_frame>10 years</time_frame>
    <description>Estimated by quality of life questionnaire (SF36) at start, 1, 3, 5 and 10 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of transgender treatment on aggression</measure>
    <time_frame>10 years</time_frame>
    <description>Estimated by aggression questionnaire at start, 1, 3, 5 and 10 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in maximal oxygen consumption during transgender treatment</measure>
    <time_frame>10 years</time_frame>
    <description>Estimated by test og maximal oxygen consumption (vo2max) at start, 1, 3, 5 and 10 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart function</measure>
    <time_frame>10 years</time_frame>
    <description>Ejection fraction and left ventricular muscle mass are measured by echocardiography at start, 1, 3, 5 and 10 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory function</measure>
    <time_frame>10 years</time_frame>
    <description>Forced Expiratory Volume in the first second and forced vital capacity estimated by spirometry at start, 1, 3, 5 and 10 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of testosterone, estradiol and cortisol</measure>
    <time_frame>10 years</time_frame>
    <description>Measured in serum by LCMS/MS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>circulating markers of inflammation</measure>
    <time_frame>10 years</time_frame>
    <description>CRP in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>circulating markers of cardiovascular risk</measure>
    <time_frame>10 years</time_frame>
    <description>Lipids, SuPAR in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of cortisol/cortisone</measure>
    <time_frame>10 years</time_frame>
    <description>measured in urine and hair samples by LCMS/MS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lean body mass</measure>
    <time_frame>10 years</time_frame>
    <description>Estimated by dual x-ray absorptiometry at start, 1, 3, 5 and 10 years</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Transgenderism</condition>
  <arm_group>
    <arm_group_label>transgender men</arm_group_label>
    <description>no intervention</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, urine, hair&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Persons assigned female at birth (+18 years) that either use or want to use testosterone&#xD;
        with the purpose of undergoing gender transformation. -&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Transgender men&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        none&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Andersen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>marianne andersen, Professor</last_name>
    <phone>+4565412502</phone>
    <email>msa@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louise Christensen, MD</last_name>
    <phone>+4565412502</phone>
    <email>louise.lehmann.christensen@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariannne S Andersen, Prof</last_name>
      <phone>+4565412502</phone>
      <email>msa@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Marianne Andersen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

